We are pleased to announce the equity investment of Fondation Arthritis in our company to support the clinical development of our disease-modifying osteoarthritis drug candidate.

“As a French start-up focusing on the development of 4P004, a first-in-class Disease Modifying Osteoarthritis Drug (DMOAD) the support of the institution anchoring like the Fondation Arthritis is undeniably important for scientific research and for patients.” said Prof. francis berenbaum, co-founder and CEO/CMO of 4Moving Biotech, Professor at Sorbonne University and head of the rheumatology department at St-Antoine Hospital (AP-HP) in Paris.

Last month, 4Moving Biotech has enrolled its first patient for phase I of LASARE clinical trial study.

For more information: http://bit.ly/3Grs2k1

‍

‍